Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID‐19 era
- 18 May 2020
- journal article
- letter
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (4), e13618
- https://doi.org/10.1111/dth.13618
Abstract
Click on the article title to read more.Keywords
This publication has 6 references indexed in Scilit:
- COVID-19 and immunomodulator/immunosuppressant use in dermatologyJournal of the American Academy of Dermatology, 2020
- Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic ArthritisClinical Epidemiology, 2020
- Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of PsoriasisJAMA Dermatology, 2019
- Apremilast and Phototherapy for Treatment of Psoriasis in a Patient With Human Immunodeficiency Virus2019
- Apremilast in psoriasis and beyond: Big hopes on a small moleculeIndian Dermatology Online Journal, 2019
- Apremilast: A Review in Psoriasis and Psoriatic ArthritisDrugs, 2015